MDP Stock Overview
Operates as a pharmaceutical company in Canada and the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$2.29 |
52 Week High | CA$3.16 |
52 Week Low | CA$1.44 |
Beta | 1.96 |
11 Month Change | -14.55% |
3 Month Change | 0.88% |
1 Year Change | 9.05% |
33 Year Change | -30.18% |
5 Year Change | -41.28% |
Change since IPO | -69.47% |
Recent News & Updates
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Nov 05There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Recent updates
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Nov 05There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 21Shareholder Returns
MDP | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -11.2% | -2.4% | -1.3% |
1Y | 9.0% | 20.0% | 21.4% |
Return vs Industry: MDP underperformed the Canadian Pharmaceuticals industry which returned 20% over the past year.
Return vs Market: MDP underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
MDP volatility | |
---|---|
MDP Average Weekly Movement | 7.5% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 8.3% |
10% most volatile stocks in CA Market | 17.4% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MDP has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: MDP's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 82 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
MDP fundamental statistics | |
---|---|
Market cap | CA$54.48m |
Earnings (TTM) | CA$1.51m |
Revenue (TTM) | CA$150.52m |
37.4x
P/E Ratio0.4x
P/S RatioIs MDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDP income statement (TTM) | |
---|---|
Revenue | US$108.78m |
Cost of Revenue | US$46.15m |
Gross Profit | US$62.63m |
Other Expenses | US$61.54m |
Earnings | US$1.09m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | 0.044 |
Gross Margin | 57.57% |
Net Profit Margin | 1.00% |
Debt/Equity Ratio | 142.2% |
How did MDP perform over the long term?
See historical performance and comparison